US-depot neuer wert - 500 Beiträge pro Seite

[austrostocks]

neuaufnahme us.depot:
strong buy mit kursziel 4 USD (long --12 bis 18 monate)

Alfacell Provides Update on ONCONASE(R) Malignant Mesothelioma Phase IIIb Trial
Tuesday August 30, 8:30 am ET


BLOOMFIELD, N.J., Aug. 30 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) today provided an update on the status of its international, confirmatory Phase IIIb malignant mesothelioma trial for ONCONASE® (ranpirnase), the Company`s lead investigational drug candidate:

* Nearly 90% of the patients required per the study design for full
patient accrual are now enrolled.
* Active patient enrollment is ongoing at leading cancer centers in the
United States, Canada, Germany, Italy, Poland, Australia and New
Zealand.
* Earlier this year, the Company reported that recent regulatory changes
in several large, non-EU countries had delayed the opening of new sites
for the study. The Company is now pleased to announce that government
approvals have been obtained and sites recently opened in Russia,
Romania, Mexico and Brazil.

"This progress illustrates our strong focus on accelerating the completion of the ONCONASE malignant mesothelioma clinical program," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "Our extensive, global patient recruitment efforts continue to move us closer to achieving important milestones, such as completing patient enrollment for the Phase IIIb study and the non-clinical sections of the rolling NDA."

The Company will continue to provide updates on the trial as key developments occur.

About Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell`s lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com.

About the ONCONASE Phase IIIb Study

ONCONASE, Alfacell`s lead investigational drug candidate, is currently being evaluated in a centrally randomized, open label, confirmatory Phase IIIb trial as a treatment for malignant mesothelioma (MM), an asbestos-related cancer that afflicts approximately 4,000 people in the U.S. each year. Over 40 U.S. and international sites are participating in the study. For more information, please visit www.centerwatch.com/alfacellmeso.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company`s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company`s periodic filings with the Securities and Exchange Commission. By making these forward- looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.


Contact:
Alfacell Corporation:
Kuslima Shogen
Robert Love
[phone]
[e-mail]

Investor/Media Relations
Elite Financial Communications
Stephanie Noiseux
[phone]
[e-mail]

[austrostocks]

kurzer nachtrag..
cave
an der nasdaq nur mit sehr engen limits ordern....

viel erfolg

[austrostocks]

und weil es gar so schön ist, der kernsatz des heutigen releases:

According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012.

und noch eines.. dieser thread ist nur für investoren gedacht, also kein push und auch nichts für die bäckersleute, weil die aktie ohnehin nur in den usa gehandelt wird.

stay cool

[carlo49]

hi
der langfristchart ist ja nicht so der knaller
aber, sag mir bitte: woher kommt die fantasie?
vielen dank

[austrostocks]

also der chart ist bei diesem wert jetzt nicht mehr von großer bedeutung.
die story ist simpel: ein krebsmedikament, das in einer testreihe bei 90% der patienten eine ausheilung der krankheit bewirkte..
noch dazu, wo diese tumorart bisher als sehr schwierig therapierbar galt.
wenn das präparat die zulassung bekommt... na dann.
aúßerdem verfügt das unternehmen bereits über standbeine in europa und vor allem auch in russland.

aber wie bei jeder aktie gilt auch hier: jeder investor sollte sich im detail über das unternehmen, die geschäftsfelder und die marktchancen informieren, ehe er (sie) anteile zeichnet.
wir glauben an die story und sind mit an bord.

viel erfolg